Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients

Phase 3

Completed

Conditions: Renal Transplantation

Interventions: Drug: Cyclosporine
Drug: Daclizumab
Drug: Mycophenoate Mofetil
Drug: Prednisolone
Drug: Sirolimus

First Posted Date: 2016-02-19

Last Posted Date: 2016-02-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 237

Registration Number: NCT02686619

Tocilizumab Real-Life Human Factors (RLHFs) Validation Study

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Device: AI-1000 G2
Drug: Tocilizumab

First Posted Date: 2016-02-15

Last Posted Date: 2019-04-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 91

Registration Number: NCT02682823

Locations: 🇺🇸
Metroplex Clinical Research, Dallas, Texas, United States
🇺🇸
Pacific Arthritis Ctr Med Grp, Santa Maria, California, United States
🇺🇸
Valerius Medical Group & Research Ctr of Greater Long Beach, Los Alamitos, California, United States

and more 5 locations

A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease

Phase 1

Completed

Conditions: Celiac Disease

Interventions: Drug: Placebo
Drug: RO5459072

First Posted Date: 2016-02-10

Last Posted Date: 2017-08-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 19

Registration Number: NCT02679014

Locations: 🇬🇧
Hammersmith Medicines Research Ltd., London, United Kingdom

A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Device: AI-1000 G2
Device: PFS-NSD
Drug: Tocilizumab

First Posted Date: 2016-02-10

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 189

Registration Number: NCT02678988

A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: TNF inhibitor/TCZ

First Posted Date: 2016-02-10

Last Posted Date: 2018-07-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 200

Registration Number: NCT02679001

Locations: 🇸🇪
Örebro Uni Hospital; Rheumatology, Oerebro, Sweden
🇸🇪
Mälarsjukhuset; Reumatologkliniken, Eskilstuna, Sweden
🇸🇪
Arvika Sjukhus; Reumatologimottagningen - Medicinmottagningen, Arvika, Sweden

and more 8 locations

Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)

Completed

Conditions: Carcinoma, Basal Cell

Interventions: Drug: Vismodegib

First Posted Date: 2016-02-04

Last Posted Date: 2019-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 67

Registration Number: NCT02674009

Locations: 🇩🇪
Klinik Johann Wolfgang von Goethe Uni; Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt, Germany

A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Other: No intervention

First Posted Date: 2016-02-04

Last Posted Date: 2020-03-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 200

Registration Number: NCT02673710

Locations: 🇧🇪
Onze Lieve Vrouwziekenhuis Aalst, Aalst, Belgium
🇧🇪
Jessa Zkh (Campus Salvator), Hasselt, Belgium
🇧🇪
Grand Hôpital de Charleroi Notre Dame, Charleroi, Belgium

and more 20 locations

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Cobimetinib
Drug: Idasanutlin
Drug: Venetoclax

First Posted Date: 2016-02-01

Last Posted Date: 2022-01-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 88

Registration Number: NCT02670044

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇫🇷
Institut Paoli Calmettes, Marseille, France

and more 14 locations

A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).

Phase 3

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: Crenezumab

First Posted Date: 2016-02-01

Last Posted Date: 2020-07-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 813

Registration Number: NCT02670083

Locations: 🇺🇸
Brain Matters Research, Inc., Delray Beach, Florida, United States
🇺🇸
Quantum Laboratories, Deerfield Beach, Florida, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 192 locations

A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany

Completed

Conditions: Breast Cancer

First Posted Date: 2016-01-28

Last Posted Date: 2019-03-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 15000

Registration Number: NCT02666261

Locations: 🇩🇪
OptiPath Gemeinschaftspraxis für Pathologie, Frankfurt, Germany
🇩🇪
Gemeinschaftspraxis für Pathologie Dr. Dykgers, Dr. Langwieder, Dr. Rees, Dortmund, Germany
🇩🇪
Universitätsklinikum Erlangen; Pathologisches Institut, Erlangen, Germany

and more 61 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy